Method of treating chronic opisthorchiasis in patients with rosacea
SUBSTANCE: praziquantel is administered in a single dose of 20 mc/kg for the first day of treatment in the daytime, and withdrawn; on the following day, the conducted therapy is added with introducing Gelmicide, a biologically active food supplement, in a dose of 2 capsules with meals for 21 days; the course is repeated 10 days later in a dose of 2 capsules 2 times a day with meals for 14 days.
EFFECT: reducing the rate of complications and increasing the high dishelminthisation efficacy.
The invention relates to medicine, dermatology and can be used for the treatment of chronic opisthorchiasis in patients with rosacea.
The closest to the proposed is a method for the treatment of patients with combined pathology with praziquantel, which is prescribed in the usual dose 60 mg/kg of body weight over night scheme in 3 divided doses every 4 hours [Beloborodova E. I.; N. To. Bychkova Chronic opisthorchiasis. A modern view of the treatment"]. The effectiveness of deworming was 100%. However, for patients with rosacea this treatment causes a complication process of the skin in the form of appearance of new lesions, especially in the first days after deworming, accompanied by itching, which required additional detoxification gemodez within 5 days.
A new technical result - the reduction of complications in high-efficiency deworming.
To solve this problem the method of treatment of chronic opisthorchiasis in patients with rosacea, by the introduction of praziquantel in the period of the stationary stage of the process, and praziquantel administered at a dose of 20 mg/kg of body weight once in the afternoon, the following day, administered biologically active food Supplement "Helmeted" 2 capsules 2 times daily before meals for 21 days, after 10 days administered biologically active dobak� to food "Helmeted" to 2 tablet 2 times daily before meals for 14 days.
The method is as follows:
The patient undergoes a physical examination (General blood test, General urine analysis, biochemical analysis of blood), liver ultrasound, duodenal intubation.
While in the duodenal bile eggs opistorhisov patient conduct deworming on an outpatient basis.
Before treatment to relieve the acute patient with rosacea outpatient receives the following treatment: detoxification therapy (a solution of sodium thiosulfate 30% 10 ml/No. 10), antihistamines (claritin 1 tablet 1 time a day for 10 days), vitamin (Ascorbic acid 5% by 1.0 ml of 1 times a day for 10 days, Thiamine bromide 6% in 1.0 ml of 1 times a day for 10 days), sedatives (Afobazol 1 tablet 3 times a day for 10 days), antiparasitic treatment (metronidazole 0.25 mg 3 times a day for 21 days). Externally: gel Rozex.
Further, in the outpatient setting, the patient receives praziquantel in the daytime at a dose of 20 mg/kg of body weight once (after lunch). On the following day appointed for the reception of biologically active additives to food "Helmeted" 2 capsules 2 times daily before meals for 21 days, after 10 days, appoint a reception of biologically active additives to food "Helmeted" 2 capsules 2 times daily before meals for 14 days. Externally: gel Rozex.
Dietary Supplement � food "Helmeted" is a phytocomplex, consisting of herb mugwort, Cassia angustifolia, the fruit of cumin and dill and buds of the clove tree, processed by special technology.
Indications for use: Giardia, opisthorchiasis, ascariasis, chlamydia, chronic cholecystitis, cholangitis, hepatitis, biliary dyskinesia (JIT), atonic colitis, skin diseases (urticaria, skin Allergy, psoriasis) and goiter.
Method of application: adults and children over 12 years: 2 capsules during the day and 2 capsules in the evening with a glass of water (150-200 ml.). Course duration is 20 days. For preventive purpose to repeat the course in 2-3 months. For the purpose of cleansing the body of waste products of parasites in the process of taking the drug it is desirable to periodically clean the intestines via laxatives or enemas, as well as tyubazh liver after completing the course.
Contraindications: do not consume during pregnancy and when you are hypersensitive to herbs that are part of Germicide".
Release form: Hard capsule p/e of the Bank - 50 hard capsules (0.4 g).
Manufacturer: LLC "ROS", NOVOSIBIRSK, Russia
The dose of praziquantel reduced in 3 times against the commonly used by combining with a drug of plant origin. Dose and mode of application of praziquantel chosen based on�upon clinical observations. Treatment of opisthorchiasis spend in the stationary phase of psoriasis, so as not to cause exacerbation of the skin process. Praziquantel is administered in the daytime and in the outpatient setting for the patient's comfort, without compromising the quality of life, gives a high economic impact because they do not need to occupy a bed in hospital. The treatment can be carried out without interrupting the normal life of the patient. After the course of treatment carried out sensing control, according to which determined the effectiveness of deworming. The course "Helmeted" (21 days) is necessary and sufficient for treatment of this category of patients. When conducting deworming during the period of less than 21 days reduced the effectiveness of deworming and the lengthening of the course of treatment more than 21 days leads to additional side effects, undesirable for patients with rosacea. In the daytime the drug is given for the convenience of care for patients, in 2 divided doses to increase the concentration of the drug in order to more effectively carry out deworming. Dose 2 capsules 2 times a day for 21 days is necessary and sufficient for an effective deworming. Additionally in 10 days "Helmeted" is assigned to fix the achieved results. Dosage 2 capsules 2 times a day for 14 �it been selected on the basis of clinical observations.
Patient Raboteau T. O., 24 years old, went to a Regional hospital in the city of Tomsk with a diagnosis of Chronic opisthorchiasis. Chronic acalculous cholecystitis in a stage of moderate exacerbation. Biliary dyskinesia hypokinetic type. Related diagnosis: Rosacea papulopustulosa form, II subtype.
Upon receipt complained of heaviness in the right hypochondrium, a constant bitter taste in the mouth, nausea, decreased appetite, anxiety.
From history revealed that the patient is suffering from rosacea for about 3 years. Last aggravation appeared 1 month ago. Associates with exposure to the sun. The following treatment was performed: detoxification therapy (a solution of sodium thiosulfate 30% 10 ml/No. 10), antihistamines (claritin 1 tablet 1 time a day for 10 days), vitamin therapy (Askorbinova acid 5% by 1.0 ml of 1 times a day for 10 days, Thiamine bromide 6% in 1.0 ml of 1 times a day for 10 days), sedatives (Afobazol 1 tablet 3 times a day for 10 days). Externally: Rozex.
The last 2 years began to disturb the heaviness in the right hypochondrium, periodic pain in this area, intolerance to fatty foods, nausea, anxiety.
Out-patient physical examination, ultrasound, duodenal intubation.
In General, the analysis of blood eosinophilia of up to 7%. In General, the analysis of mo�and - no pathological changes. Indicators of biochemical studies of blood in the normal range.
According to chromatic duodenal revealed dykinesia gallbladder hypokinetic type: gallbladder bile expired in a large volume of 80 ml (at a rate of 60 ml), time to expiration was extended to 35 minutes (at a rate of up to 21 min). Revealed hypotension sphincter of Oddi.
Microscopy bile found eggs opistorhisov (4-5 in field of view).
According to the ultrasound of the gallbladder volume was increased and amounted to 70 cm3(at a rate of 40-60 cm3).
Objective: asthenic physique. On the face, centrofacial (forehead, nose, cheeks, chin), which is the erythema with indistinct borders. On the background of erythema are small pink papules, elastic consistency. Is peeling in the nasolabial folds. On the skin of nasolabial folds are visible isolated pustules with pus.
Tongue coated yellow tinge at the base. The lungs and heart without pathology. The abdomen is soft, palpation in the right hypochondrium moderately painful. Positive symptoms of Kerala and Murphy.
For the treatment of chronic opisthorchiasis and hypotension gallbladder was appointed method of treatment according to the invention: after removal of exacerbation of rosacea was prescribed praziquantel at a dose of 20 mg/kg, � the following day, "Helmeted" 2 capsule 2 times daily with meals for 21 days.
Treatment the patient underwent right. After deworming with praziquantel side effects were noted. The appearance of lesions on the skin, itching was observed. On the 10th day of application "Helmeted" gone feeling of heaviness in the right hypochondrium, bitter taste in the mouth, by the end of treatment there was a sense of nausea and his appetite. After treatment of chronic opisthorchiasis control were conducted duodenal intubation, ultrasound. According to fractional duodenal gallbladder bile volume and the time to expiration is normalized to 65 ml (at a rate of 60 ml) and 24 min (at a rate of 21 min). When bile microscopy revealed individual eggs opistorhisov. According to the ultrasound of the gallbladder volume was 60 cm3that is the norm. During the week after treatment was achieved regression of the manifestations of rosacea. 10 days after the end of treatment was prescribed a course of drug treatment "Helmeted" 2 capsules 2 times a day for 14 days. A month after the treatment, the patient noted improvement of health, the complaints of the digestive tract did not show disappeared nausea, appetite returned to normal. Repeated duodenal intubation. Microscopic examination of eggs opistorhisov been identified. Skin process was in stage regression.
This method treated 7 sick� rosacea in combination with chronic opisthorchosis. Side effects of the skin, gastrointestinal tract in the treatment of this method was observed. The effectiveness of deworming was 83.3%.
Thus, the proposed method allows to treat patients with comorbidity with optimally matched combination of highly effective antihelminthic drug with biologically active additive to food "Helmeted", derived from plant materials. This gave the opportunity to three times lower dose highly effective, but highly toxic praziquantel and more gently with a sufficiently high efficiency (83,3%) to treat patients with rosacea.
A method for the treatment of chronic opisthorchiasis in patients with rosacea, consisting in the carrying out deworming with praziquantel during remitting exacerbation, characterized in that on the first day of treatment administered praziquantel at a dose of 20 mg/kg once in the daytime, and on the following day, appoint a biologically active food Supplement “Helmeted” 2 capsules 2 times daily with food for 21 days, after 10 days, appoint a biologically active food Supplement “Helmeted” 2 capsule 2 times daily with meals for 14 days.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to dihydroazol compounds of formula (I) wherein R1 means a C1-C6alkyl or C1-C6haloalkyl; X means a phenyl, which can be unsubstituted or substituted by one or more halogens, C1-C12alkyls, C3-C10cycloalkyls, C1-C12haloalkyls, C2-C12alkenyls, C2-C12haloalkenyls, C1-C12alkinyls or C1-C12haloalkynyls; A1 means hydrogen, and A2 means CR7R8; G means G-1 or G-2; B1, B2, B3, B4 and B5 independently mean N or C-R9; Y means Y-1, Y-2, Y-3, Y-4, Y-5, Y-6, Y-7, Y-8 or Y-9 (as it is presented in the patent claim); R2, R3 independently mean hydrogen, C1-C12alkyl, C1-C12haloalkyl, thio-C1-C12alkyl, C1-C12alkylthio-C1-C12alkyl, hydroxy-C1-C12alkyl, C1-C12alkoxy-C1-C12alkyl, C2-C12alkenyl, C2-C12haloalkenyl, C2-C12alkynyl, C2-C12haloalkynyl, C3-C10cycloalkyl; R4 independently means hydrogen, C1-C12alkyl, C1-C12haloalkyl, thio-C1-C12alkyl, C1-C12alkylthio-C1-C12alkyl, hydroxy-C1-C12alkyl, C1-C12alkoxy-C1-C12alkyl, C2-C12alkenyl, C2-C12haloalkenyl, C2-C12alkynyl, C2-C12haloalkynyl or C3-C10cycloalkyl; R7 and R8 independently mean hydrogen, C1-C12alkyl or C1-C12haloalkyl; R9 means hydrogen, halogen, C1-C12alkyl, C1-C12haloalkyl, C1-C12alkenyl, C2-C12haloalkenyl, C2-C12alkynyl or C2-C12haloalkynyl; each R10, R11, R12 and R13 independently means hydrogen, C1-C12alkyl or C1-C12haloalkyl; or R10 together with R11 form =O, =S or =NR2; or R12 together with R13 form =O, =S or =NR2; n=1. The invention also refers to compositions for treating or preventing endoparasitic infections or ectoparasitic invasions in animals and for protecting crops, plants, planting stock or timber against pests, to a method of treating or preventing endoparasitic infections or ectoparasitic invasions in animals, to a method for protecting crops and growing plants against pest attacks or invasions, to a method for preventing or controlling a pest invasion on site, and to using the compounds of formula (I).
EFFECT: compounds of formula (I) applicable for preventing or treating endoparasitic infections or ectoparasitic invasions in animals, and also as pesticides
30 cl, 2 tbl, 8 ex
SUBSTANCE: method includes carrying out complex treatment at the background of diet therapy. Intake of antihelmintic of vegetable origin and immunomodulator is carried out daily with washing down each of them with 200 ml of radon water. Intestinal lavage is performed every second day. On days of performing intestinal lavage, patient takes bath with radon water in the morning before lavage, with performing underwater hydrodynamic massage (UHM) on other days. On days, when intestinal lavage is not performed, sessions of sound therapy are carried out after UHM.
EFFECT: method provides correction of biological age of organism as prevention of premature ageing.
3 cl, 4 tbl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and represents a sustained release solid therapeutic agent containing a combination of praziquantel with emodepside, polyvinylpyrrolidone and/or a polyvinylpyrrolidone derivative in an amount of 10 to 50 wt %, polyvinylpyrrolidone and/or the polyvinylpyrrolidone derivative is a mixture of one short-chain polyvinylpyrrolidone and one polyvinylpyrrolidone or the polyvinylpyrrolidone derivative with longer chains, and at least one excipient in an amount of 5 to 80 wt %.
EFFECT: sustained release of active substances and no lump formation in the gastrointestinal tract if two or more tablets taken.
4 cl, 7 ex, 4 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to an albendazole-based composition. The claimed composition consists of a substance of albendazole and arabinogalactane polysaccharide from Siberian larch or Gmelin with weight ratios of the components albendazole : arabinogalactane 1:5-20.
EFFECT: invention possesses the higher anti-opisthorchosis pharmaceutical activity than albendazole, and does not cause the toxic injury of hepatocytes.
3 cl, 7 dwg, 2 tbl, 4 ex
SUBSTANCE: invention relates to an amide of 2-(3-methyl-6-methoxy-7-ethoxy-3,4-dihydroisoquinolyl-1)-ethanoic acid hydrochloride of formula 1
EFFECT: obtaining a novel isoquinoline derivative, having anthelmintic activity.
SUBSTANCE: what is described is a gel containing structured nanovesicles - niosomes prepared from silicone compounds with enclosed albendazole, anthelmintic preparation.
EFFECT: invention enables extending the range of application of the anthelmintic preparations by reducing dyspeptic reactions that makes them applicable in both adults, and children suffering gastrointestinal diseases.
SUBSTANCE: method of production of anthelmintic for group treatment of sheep with monieziasis is as follows: first, in the chemical reactor with anchor stirrer in polyethyleneglycol warmed to boiling the niclosamide is dissolved in the ratio of 4:1. Then, the resulting solution is added with beet molasses, lecithin, and sodium chloride in a ratio of 25:3:1:1 and mixed thoroughly. After that the mixture is added to oat flour - filler - in a ratio of 30:70 and mixed thoroughly until complete impregnation of the filler. The resulting mixture is subjected to granulation, the granule diameter is 3 mm. 1 kg of the agent contains 4% of active ingredient.
EFFECT: invention provides saving of the substance to prepare the agent, 5 times reduction of the therapeutic dose, decreased toxicity of the agent, increased bioavailability and improved eating of the agent, elimination of possible loss of active ingredient in dehelmintisation of animals.
SUBSTANCE: declared invention refers to veterinary science and aims at treating the diseases caused by giardia. The declared drug as an active substance contains Nifurtimox.
EFFECT: using the declared drug is high effective in treating the diseases caused by giardia.
3 cl, 2 tbl, 2 ex
SUBSTANCE: invention relates to medicine, namely to endocrinology, and deals with treatment of diabetes mellitus, complicated by accompanying diseases, in particular, by parasite invasions. For this purpose electro-activated water solutions of inorganic salts are introduced at the background of antihyperglycemic medications. On first 5 days solution of anolyte (EWS-A) with redox potential (RP) from +700 to +800 mV and with pH from 6.0 to 4.5, after which for 5 days introduced is catholyte solution (EWS-C) with RP from -400 to -600 mV and pH from 9.5 to 10.5; then for 10 days introduced are heated to +36°C - +37°C EWS-C and EWS-A are introduced with their alternation for 24 hours. In case of accompanying parasite invasion, EWS-A in combination with anti-parasitic vegetable medications in form of rectal microclysters for first 5 days of treatment is additionally introduced for first 5 days of treatment. EWS-C in combination with rectal microclysters with probiotic additives is introduced for the following 10 days. In case of detection of Opisthorchida, biltricide is introduced on the 15-th day in dose 75 mg/kg, and duodenal probing with anti-parasitic medication is carried out on the 16-th day. Starting with the 6-th day and to the completion of treatment (21-st day) fermented milk product "Narine" is administered in dose 1 tablespoon 3 times per day 30-40 minutes before meal.
EFFECT: mode of introducing electro-activated water solutions in complex with probiotics and anti-parasitic preparations provides efficient treatment of parasite invasions in combination with gradual normalisation of carbohydrate and lipid exchange in patients with diabetes mellitus.
2 cl, 2 ex, 4 tbl
SUBSTANCE: declared group of inventions refers to veterinary science and aims at controlling blood-sucking parasites and consuming parasites. The composition contains an antiparasitic effective subtoxic amount of imidacloprid in a single dose making 0.25 mg/kg to 30 mg/kg for oral delivery. Imidacloprid is the only antiparasitic being an ingredient of the composition. What is declared is using the above composition. The subtoxic amount of imidacloprid in a single dose makes 0.25 mg/kg to 30 mg/kg. The infestation is eliminated within 1-72 hours after administration of the single dose.
EFFECT: declared group of inventions provides effective elimination of blood sucking parasites and blood consuming parasites.
24 cl, 6 tbl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of pharmaceutics, namely, deals with compounds of formula , suitable for reduction of regulation of biological activity of melanocortin-5 receptor (MC5R). Such diseases and/or conditions include, but are not limited by, acne, seborrhoea, seborrheic dermatitis, cancer and inflammatory diseases.
EFFECT: compounds of claimed invention can be applied for treatment of diseases and/or conditions, in which reducing regulation of MC5R is favourable.
3 cl, 109 ex, 7 tbl
SUBSTANCE: invention relates to a compound of formula (I) : or a salt thereof, wherein R1 and R5 are independently selected from H, OH and alkoxy; R2-R4 and R6-R8 are independently selected from H, OH, F, Cl, Br and I; R9 and R10 are C2-C8 alkenyl; under the condition that at least one of R1, R5 and R7 is OH or alkoxy; at least one of R2-R4, R6 and R8 is F, Cl, Br or I; and R2 and R6 are Cl. The invention also relates to an antibacterial composition and treatment methods.
EFFECT: improved properties.
18 cl, 7 ex, 10 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, and represents a pharmaceutical composition in the form of gel, which contains clindamycin phosphate, a combination of gel-forming polymer and hydrophilic dispersion phase, pH control agent, allantoin and lauryliminodipropionate sodium tocopheryl phosphate; the ingredients of the composition are taken in certain ratio, in g per 100 g.
EFFECT: invention provides the high level of antibacterial activity and stability.
5 cl, 1 tbl
SUBSTANCE: present group of inventions refers to medicine, namely to dermatology, and concerns treating telangiectasia or related symptoms. To this effect, an involved skin area is coated with a composition containing from approximately 0.4 wt % to approximately 0.6 wt % brimonidine providing its blood serum or plasma concentration, Cmax of approximately 54±28 pg/ml or less and AUC0-24h of approximately 568±277 pg·h/ml or less.
EFFECT: method provides the effective treatment of telangiectasia or related symptoms with no side local and systemic effects.
20 cl, 6 dwg, 6 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the pharmaceutical industry and represents a composition for treating acne, rosacea and hyperpigmentation, in the form of a gel which contains anchoic acid, a hydrophobic ingredient, a non-aqueous solvent, an emulsifying agent, a gel-forming polymer, a preserving agent, a pH control agent and additionally methylpyrrolidone with anchoic acid having a particle size of less than 100 mcm, while anchoic acid is related to methylpyrrolidone as 1:0.025 to 1:4.
EFFECT: invention provides easy penetration of anchoic acid through a horny layer and its resolution into the oil grand ducts and between skin cells, providing high concentration of anchoic acid that promotes better antibacterial, keratolytic and de-pigmentation effects.
5 cl, 2 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to a compound of Formula
where Y represents a group of formula -(CR9R10)-; X is selected from the group, consisting of -C(=O)-, -OC(=O)-, -NHC(=O)-, -(CR11R12)- and -S(-O)2-; Z represents a group of formula -(CR13R14)q-; R1 is selected from the group, consisting of C1-C12alkyl, optionally substituted with one substituent, selected from naphthyl, indole and biphenyl; C2-C12alkenyl, substituted with a substituent, selected from thienyl, naphthyl and phenyl, with the said phenyl being optionally substituted with 1-2 substituents; selected from halogen, trifluoroalkyl, C1-C6alkyl, methoxy and hydroxy; C3-C6cycloalkyl; C6-C10aryl, optionally substituted with 1-2 substituents, selected from halogen, phenyl, amino, phenoxy, C1-C6alkyl, methoxy, hydroxyl and carboxy; and C4-C9heteroaryl, selected from indole, quinoline, quinoxaline, benzofuranyl, benzothiophene, benzimidazole, benzotriazole, benzodioxin, benzothiasole, pyrazole, furyl and isoxazole, optionally substituted with a substituent, selected from C1-C6alkyl and phenyl; R2 and R3 each is independently selected from the group, consisting of H and C1-C12alkyl; R4a is selected from the group, consisting of H, C1-C12alkyl, optionally substituted with phenyl; C2-C12alkenyl, C3-C6cycloalkyl, C6aryl, C(=O)R15, C(=O)NR15R16, C(=O)OR15, SO2R15 and -C(=NR15)-NR16R17; R4d represents hydrogen or R4a and R4b, taken together with a nitrogen atom, which they are bound to, form an optionally substituted heterocyclic fragment, selected from piperidine, morpholine, pyrrolidine and azetidine, where the substituent is selected from C1-C12alkyl, hydroxy, halogen, carboxy and oxo; each R5a and R5b represents H, or R6, R7 and R8 each is independently selected from the group, consisting of H, C1-C12alkyl, C3-C6cycloalkyl, C6-C10aryl, optionally substituted with halogen, or taken together with a carbon atom, which they are bound to, two or more of R6, R7 and R8 form a fragment, selected from the group, consisting of C2-C12alkenyl; C3-C6cycloalkyl, optionally substituted with C1-C6alkyl; C6aryl, optionally substituted with 2 substituents, selected from halogen; each R9 and R10 represents H or C1-C12alkyl, substituted with naphthyl; each R11 and R12 represents H; R13 and R14 represent H, or each R15, R16 and R17 is independently selected from the group, consisting of H, C1-C12alkyl, C3-C6cycloalkyl, C6aryl, substituted with one substituent, selected from C1-C6alkyl; and C5-heteroaryl, additionally containing one nitrogen atom, with the said heteroaryl representing pyridyl; q represents an integer number, selected from the group, consisting of 2, 3 and 4; r represents 1; or its pharmaceutically acceptable salt. The invention also relates to particular compounds of 1,4-diazepan-2-one derivatives.
EFFECT: obtaining 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists.
21 cl, 7 tbl, 110 ex
SUBSTANCE: invention refers to medicine, namely to dermatology, and can be used for selecting a therapeutic approach to acne in females by examining biological fluids and prescribing preparations depending on the clinical findings. The biological fluids are blood and urine; blood serum hormones and steroid urine profile are tested, and the derived values are compared to the standard norms specific for the absence of acne, while the preparations are prescribed according to the comparison results. Specifically, if observing an increase of blood luteinising hormone up to 16 mIU/ml, testosterone up to 4 ng/ml, an increase of urine androsterone up to 20 mcmole/24 hours, etiocholanolone up to 11 mcmole/24 hours, total 17-ketosteroids up to 35 mcmole/24 hours, van de Calseyde's discriminant up to 3, the combined oral contraceptive Jess with the anti-androgenic effect. If also observing an increase of immunoreactive protein up to 12.90 mcUnit/ml and insulin-line growth factor 1 up to 361.04 ng/ml, the combined oral contraceptive Jess and Metformine or Metformine are prescribed. If observing a decrease of blood oestradiol up to 140 pmole/l or an increase of the concentration of luteinising hormone up to 7 mIU/ml, dihydroepiandrosterone sulphate up to 4 mmole/l, 17 - hydroxyprogesterone up to 4 nmole/l and testosterone up to 4 nmole/l in blood and an increase of urine androsterone up to 17 mcmole/24 hours, etiocholanolone up to 17 mcmole/24 hours, 11 - ketoandrosterone up to 2.5 mcmole/24 hours, 11 - ketoetiocholanolone up to 2.5 mcmole/24 hours, 17 - ketosteroids up to 50 mcmole/24 hours and van de Calseyde's discriminant up to 3, the glucocorticoid Metypred is prescribed. The high blood concentration of luteinising hormone up to 15 mIU/ml, dihydroepiandrosterone sulphate up to 6.82 mcmole/l, 17 - hydroxyprogesterone up to 4 nmole/l and an increase of urine androsterone up to 19.5 mcmole/24 hours, etiocholanolone up to 16 mcmole/24 hours, dihydroepiandrosterone up to 7 mcmole/24 hours, 17 - ketosteroids up to 45 mcmole/24 hours and van de Calseyde's discriminant up to 3.5 enables using the combined oral contraceptive Jess and the glucocorticoid Metypred. And the preparation Dostinex is prescribed in observing the above values in a combination with an increase of blood prolactin up to 750 IU/ml and a decrease of blood oestradiol up to 95.48 pcg/ml.
EFFECT: method enables providing higher therapeutic selectivity and clinical effectiveness in acne without the need of thorough examination to be conducted.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of pharmaceutics, in particular represents composition for topic application, which includes, into physiologically acceptable medium at least one derivative of naphthoic acid, benzoylperoxide and at least one film-forming component.
EFFECT: invention is characterised by the fact that said compound of naphthoic acid and benzoylperoxide are in dispersed in said composition form.
23 cl, 14 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to an herbal formulation of topical nanoemulsion for treating acne-related skin disorders. The above formulation contains an aqueous phase comprising a therapeutic agent, rose water and/or lemon juice, and an oil phase containing an essential oil, a non-ionic surfactant and an accessory surfactant. The aqueous and oil phases are related within the range of 1:1 to 1:2, while a particle size of the herbal formulation is less than 5 nm. The essential oil is presented by tea tree oil, basil oil, rosemary oil, lavender oil, jojoba oil, bergamot oil, clove oil and peppermint oil. The invention also refers to a method for preparing the herbal formulation which involves providing the aqueous and oil phases, mixing the above phases to produce a mixture to be emulsified with the non-ionic surfactant to prepare a macroemulsion. The prepared macroemulsion is mixed with ethanol to produce a nanoemulsion with a particle size less than 5 nm.
EFFECT: invention provides the herbal formulation with good penetration, prolonged effect causing no irritation.
8 cl, 4 dwg, 7 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to compounds of the following formula , in which n equals integer number from 1 to 15, m equals 0, 1, 2 or 3, and R represents hydrocarbon chain of polyunsaturated fatty acid, selected from omega-3 and omega-6 polyunsaturated fatty acids, and to method of obtaining them.
EFFECT: development of pharmaceutical or cosmetic composition based on said compounds and to method of acne or seborrheic dermatitis treatment for cosmetic purposes.
16 cl, 4 dwg, 2 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of organic chemistry, namely to novel heterocyclic compounds of formula (1) and/or to their pharmaceutically acceptable salts, where A1 represents CH; A4and A5 independently represent CR2 or N; A2 and A3 together with ring B represent 5-membered heteroaryl or heterocycle, with said 5-membered heteroaryl or heterocycle being selected from where t represents 1 or 2; and R3 is independently selected from H, C1-C6 alkyl, C6-aryl, C3-C6-membered cycloalkyl, C(O)NRcRd, -ORb, heteroaryl, representing pyridine, and heterocycle, representing piperidine and tetrahydropyran; and each of said alkyl, aryl, cycloalkyl, heteroaryl and heterocycle can be substituted with one group, independently selected from C1-C6 alkyl, possibly substituted with one substituent, selected from -CONMe2, C3-membered cycloalkyl, -CN, -OMe, -pyridine, tetrahydropyran, -CO-morpholine, -CO-pyrrolidine, (3-methyl)oxetane; -OH; -C(O)Ra; -CN; -C(O)NRcRd; -NRcRd; -ORb; -S(O)nRe; halogen, and substituted with one group -COMe heterocycle, representing piperidine, on condition that when A4 represents CR2, A2 and A3 together with ring B are selected from structure (3), (5) or (6); represents single bond or double bond; R1 represents heteroaryl, representing 6-membered or 9-10-membered aromatic mono- or bicyclic ring, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur; possibly substituted with one or two groups, independently selected from C1alkyl, C2alkinyl, -NRcRd, -NRcS(O)nRe, -ORb, halogen, halogenalkyl; R2 is independently selected from H; each Ra, Rb, Rc, Rd, and Re is independently selected from H; C1-C4alkyl, possibly substituted with one substituent, selected from -OH, -OMe, -CN, -NH2, -NMe2, C3-cycloalkyl; C2-C3alkenyl; C3alkinyl; C6aryl, possibly substituted with one or more substituents, selected from fluorine or methyl group; C3-membered cycloalkyl, possibly substituted with one substituent, selected from -OH and -CN; halogenalkyl; heteroaryl, representing pyridine; and substituted with one methyl group heterocycle, representing piperidine, or Rc and Rd together with atom (atoms) which they are bound to form 5-6-membered heterocyclic ring, representing pyrrolidine or morpholine; and in each case n is independently equal 2. Invention also relates to particular compounds, pharmaceutical composition, based on claimed compounds; method of inhibiting PI3K and/or mTOR activity and to application of claimed compounds.
EFFECT: novel compounds, useful for inhibiting PI3K and/or mTOR activity have been obtained.
15 cl, 16 ex